Parvovirus VLP 

Parvovirus virus-like particles (VLPs) are non-infectious, self-assembled protein structures that mimic the morphology and antigenicity of parvoviruses without containing their genetic material. Parvoviruses are small, non-enveloped, single-stranded DNA viruses that infect a range of hosts, causing diseases in animals and humans, such as canine parvovirus (CPV), feline panleukopenia virus (FPV), and human parvovirus B19.

Structure of Parvovirus VLPs

Parvovirus VLPs are composed of the major structural proteins of the virus:

  • VP1 and VP2 Capsid Proteins: These proteins self-assemble into icosahedral particles, mimicking the native virus capsid. VP2 forms the primary structure, while VP1 includes unique functional domains, such as phospholipase A2, critical for viral entry and trafficking in natural infections.
Production Systems

Parvovirus VLPs are produced using various expression platforms, each with distinct advantages:

  • Bacterial Systems (e.g., E. coli): Cost-effective for high-yield production, though post-translational modifications are absent.
  • Insect Cells: Baculovirus expression systems are widely used for producing properly folded and functional VLPs.
  • Mammalian Cells: Enable accurate post-translational modifications and assembly, closely resembling native parvovirus.
  • Yeast Systems: Economical and scalable for VLP production.
Applications
  • Vaccines
    • Prophylactic Vaccines: Parvovirus VLP-based vaccines are developed to prevent infections in animals (e.g., CPV vaccines for dogs and FPV vaccines for cats) and humans (e.g., parvovirus B19).
    • Therapeutic Vaccines: Investigated for immune modulation in chronic parvovirus infections or other applications.
  • Diagnostics
    • Parvovirus VLPs serve as antigens in serological assays to detect parvovirus-specific antibodies, aiding in the diagnosis of infections.
  • Immunological Research
    • Used to study the immune responses to parvoviruses, particularly neutralization mechanisms and antigenic variability.

Parvovirus virus-like particles are a powerful tool for addressing parvovirus infections through safe and effective vaccines, diagnostics, and therapeutic applications. With their high immunogenicity, stability, and adaptability, parvovirus VLPs hold significant promise for advancing veterinary and human medicine. Ongoing research aims to optimize their production, efficacy, and accessibility for widespread use.

For Price Contact info@affigen.com 0.0 USD
AffiVLP® Parvovirus B19 VLP (VP2)
CAT# AFG-VLP-305
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
AffiVLP® Parvovirus B19 VLP (VP1)
CAT# AFG-VLP-304
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
AffiVLP® Parvovirus B19 VLP (VP1, VP2) Co-Capsid
CAT# AFG-VLP-303
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
AffiVLP® Parvovirus B19 VLP (VP1, VP2)
CAT# AFG-VLP-302
Size: 100 µg
For Price Contact info@affigen.com 0.0 USD
For Price Contact info@affigen.com 0.0 USD